title: Barrier disrupting effects of alternaria alternata extract on bronchial epithelium from asthmatic donors.
abstract: Sensitization and exposure to the allergenic fungus Alternaria alternata has been associated with increased risk of asthma and asthma exacerbations. The first cells to encounter inhaled allergens are epithelial cells at the airway mucosal surface. Epithelial barrier function has previously been reported to be defective in asthma. This study investigated the contribution of proteases from Alternaria alternata on epithelial barrier function and inflammatory responses and compared responses of in vitro cultures of differentiated bronchial epithelial cells derived from severely asthmatic donors with those from non-asthmatic controls. Polarised 16HBE cells or air-liquid interface (ALI) bronchial epithelial cultures from non-asthmatic or severe asthmatic donors were challenged apically with extracts of Alternaria and changes in inflammatory cytokine release and transepithelial electrical resistance (TER) were measured. Protease activity in Alternaria extracts was characterised and the effect of selectively inhibiting protease activity on epithelial responses was examined using protease inhibitors and heat-treatment. In 16HBE cells, Alternaria extracts stimulated release of IL-8 and TNFα, with concomitant reduction in TER; these effects were prevented by heat-treatment of the extracts. Examination of the effects of protease inhibitors suggested that serine proteases were the predominant class of proteases mediating these effects. ALI cultures from asthmatic donors exhibited a reduced IL-8 response to Alternaria relative to those from healthy controls, while neither responded with increased thymic stromal lymphopoietin (TSLP) release. Only cultures from asthmatic donors were susceptible to the barrier-weakening effects of Alternaria. Therefore, the bronchial epithelium of severely asthmatic individuals may be more susceptible to the deleterious effects of Alternaria.
authors.affiliation: Academic Unit of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, South Block, University Hospital Southampton, Southampton, United Kingdom.
authors.forename: Marina S
authors.initials: MS
authors.lastname: Leino
authors.forename: Matthew
authors.initials: M
authors.lastname: Loxham
authors.forename: Cornelia
authors.initials: C
authors.lastname: Blume
authors.forename: Emily J
authors.initials: EJ
authors.lastname: Swindle
authors.forename: Nivenka P
authors.initials: NP
authors.lastname: Jayasekera
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Dennison
authors.forename: Betty W H
authors.initials: BW
authors.lastname: Shamji
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Edwards
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Holgate
authors.forename: Peter H
authors.initials: PH
authors.lastname: Howarth
authors.forename: Donna E
authors.initials: DE
authors.lastname: Davies
mesh_terms: D000485:Allergens / Q000276:immunology*; D000528:Alternaria / Q000276:immunology*; D000946:Antigens, Fungal / Q000276:immunology*; D001249:Asthma / Q000276:immunology* / Q000378:metabolism / Q000503:physiopathology; D001980:Bronchi / Q000276:immunology* / Q000378:metabolism; D002460:Cell Line; D016207:Cytokines / Q000378:metabolism; D017097:Electric Impedance; D004789:Enzyme Activation; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism; D010539:Permeability / Q000187:drug effects; D011480:Protease Inhibitors / Q000494:pharmacology; D020545:Respiratory Mucosa / Q000276:immunology* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D000485:Allergens; D000946:Antigens, Fungal; D016207:Cytokines; D018836:Inflammation Mediators; D011480:Protease Inhibitors; D010447:Peptide Hydrolases